Security94986RPJ4 / Wells Fargo & Co. Bond (94986RPJ4)
CEO & PresidentSLOAN TIMOTHY J
IndustryNational Commercial Banks
Institutional Owners0
Common Shares Outstanding4,816,137,157 shares (as of 2018-06-30)
Related 33738MAB7 / 1st Un Natl Bk Charlotte Mtnbe Fr 6.5% 12/01/2028
33738MAA9 / 1st Un Natl Bk Charlotte Mtnbe Put 6.18% 02/22/2036
33738MAG6 / 1st Un Natl Bk Charlotte Mtnbe Put 6.919% 12/15/2036
33738KAA3 / 1st Un Natl Bk Jacksonvi Mtnbe Fr 6.18% 02/15/2036
337358BD6 / First Union Corp 6.55% Sub Debs 10/15/35
337358BA2 / First Union Corp 7.5% Sub Debs 4/15/35
66938FJU9 / Norwest Corp Medterm Notes Bk En Fr 6.75% 12/15/27
669380AW7 / Norwest Corp Sub Debentures 6.65% 10/15/23
8447HEAA4 / Southtrust Bk Atlanta Sub Mtn Put 7.74% 05/15/2025
8447HBAC6 / Southtrust Bk Birmgham Sub Mtn Fr 6.565% 12/15/27
8447HBAE2 / Southtrust Bk Birmgham Sub Mtn Put 6.125% 01/09/2028
8447HBAA0 / Southtrust Bk Birmgham Sub Mtn Put 7.69% 05/15/2025
844730AG6 / Southtrust Corp Subordinated Notes 5.8% 06/15/14
92976GAE1 / Wachovia Bk Natl Assn Mtn Sub Call 5.6% 03/15/16
92976GAB7 / Wachovia Bk Natl Assn Mtn Sub Fr 4.8% 11/01/2014
92976GAD3 / Wachovia Bk Natl Assn Mtn Sub Fr 4.875% 02/01/2015
92976GAA9 / Wachovia Bk Natl Assn Mtn Sub Fr 5% 08/15/2015
92976GAG6 / Wachovia Bk Natl Assn Mtn Sub Fr 5.85% 02/01/2037
92976GAH4 / Wachovia Bk Natl Assn Mtn Sub Fr 6% 11/15/2017
92976GAJ0 / Wachovia Bk Natl Assn Mtn Sub Fr 6.6% 01/15/2038
92978AAA0 / Wachovia Capital Trust Iii 5.80
929903AE2 / Wachovia Corp 4.875% Subordinated Notes 02/15/14
929903AJ1 / Wachovia Corp 5.250% Subordinated Notes 08/01/14
929903AM4 / Wachovia Corp 5.5% Notes 8/1/2035
92976WBJ4 / Wachovia Corp. 5.5% Senior Notes 5/1/13
929903CH3 / Wachovia Corp 5.625% Notes 10/15/2016
929903DT6 / Wachovia Corp 5.75% Notes 6/15/17
92976WBH8 / Wachovia Corp 5.75% Senior Notes 2/1/18
92976WBA3 / Wachovia Corp 5.7% Notes 8/1/2013
929771AE3 / Wachovia Corp 6.605% Notes 10/1/2025
949746NX5 / Wells Fargo 5.625% Senior Notes 12/11/17
94980VAA6 / Wells Fargo Bank Na 4.75% 02/09/15
94978SAA7 / Wells Fargo Cap X Cap Sec 5.95% 12/01/86
WFC / Wells Fargo & Co.
WFCNP / Wells Fargo & Co.
94974BFA3 / Wells Fargo & Co. 1.25% 02/13/15
94974BFG0 / Wells Fargo & Co. 1.50% 01/16/18
94974BFE5 / Wells Fargo & Co. 1.50% 07/01/15
94974BFD7 / Wells Fargo & Co. 2.10% 05/08/17
94974BFJ4 / Wells Fargo & Co. 3.45% 02/13/23
94974BFC9 / Wells Fargo Co 3.50% Senior Notes 03/08/22
949746FS5 / Wells Fargo & Co 4.625% Subordinated Notes 4/15/14
949746FJ5 / Wells Fargo & Co 4.950% Subordinated Notes 10/16/13
949746CR0 / Wells Fargo & Co 5.000% Subordinated Notes 11/15/14
WFC.PRO / Wells Fargo & Co., 5.125% Dep Shares Non-Cumul Perp Preferred Stock Series O
949746JE2 / Wells Fargo & Co. 5.125% Notes 9/15/16
WFC.PRN / Wells Fargo & Co., 5.20% Dep Shares Non-cumul Perp Cl A Preferred Stock Series N
WFC.PRP / Wells Fargo & Co., 5.25% Dep Shares Non-Cumul Perp Preferred Stock Series P
949746JM4 / Wells Fargo & Co. 5.375% Notes 2/7/35
WFC.PRX / Wells Fargo & Co., 5.50% Dep Shares Non-Cumul Class A Preferred Stock Series X
WFC.PRW / Wells Fargo & Co., 5.70% Dep Shares Non-Cumul Class A Preferred Stock Series W
WFC.PRQ / Wells Fargo & Co., 5.85% Dep Shares Fixed/Float Non-Cumul Perp Pfd Stock Ser Q
WFC.PRT / Wells Fargo & Co., 6.00% Dep Shares Non-Cumul Class A Preferred Stock Series T
WFC.PRV / Wells Fargo & Co., 6.00% Dep Shares Non-Cumul Class A Preferred Stock Series V
WFC.PRR / Wells Fargo & Co., 6.625% Dep Shares Fixed/Float Non-Cumul Perp Pfd Stock Ser R
WFC.PRL / Wells Fargo & Co., 7.50% Non-Cumul Perp Conv Cl A Preferred Stock, Series L
WFC.PRJ / Wells Fargo & Co., 8.00% Dep Shares Non-cumul Perp Cl A Preferred Stock Series J
94986RTK7 / Wells Fargo & Co. Bond
94974BFN5 / Wells Fargo & Co. Bond
WFC.PRY / Wells Fargo & Company
94974BEZ9 / Wells Fargo & Company 2.625% 12/15/16
94974BEU0 / Wells Fargo & Company 3.625% Senior Notes 04/15/15
94974BEV8 / Wells Fargo & Company 4.60% Notes 04/01/21
WFC.PRJCL / Wells Fargo & Company Depositary Shares (Each representing a 1/40th interest in a share of 8.00% Non
94974BET3 / Wells Fargo Co Mtn Be Senior Notes 3.75% 10/01/14
94986RFK2 / Wells Fargo & Co. SE
WFC.WS / Wells Fargo & Co. (Warrant)

Institutional Bond Ownership and Shareholders

Wells Fargo & Co. Bond (94986RPJ4) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Wells Fargo & Co. Bond (94986RPJ4) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-08 13F-HR CIBC World Markets Inc. Put 300,000 0 -100.00 55,050 0 -100.00

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 94986RPJ4